DGAP-News: Novavax to Present at the 25th Annual Piper Jaffray Healthcare Conference

| Source: EQS Group AG
DGAP-News: Novavax, Inc. /
Novavax to Present at the 25th Annual Piper Jaffray Healthcare

26.11.2013 / 22:05


ROCKVILLE, Md., 2013-11-26 22:05 CET (GLOBE NEWSWIRE) --
Novavax, Inc. (Nasdaq:NVAX) a clinical-stage vaccine company, announced today
that Stanley C. Erck, President and Chief Executive Officer, will present at
the 25th Annual Piper Jaffray Healthcare Conference on December 3, 2013 at
1:30pm ET in New York City at the New York Palace Hotel. 

A live webcast link for the presentation can be accessed via the company
website at www.novavax.com under Investor Info/Events. 

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company
creating novel vaccines and vaccine adjuvants to address a broad range of
infectious diseases worldwide. Using innovative proprietary recombinant protein
nanoparticle vaccine technology, the company produces vaccine candidates to
efficiently and effectively respond to both known and newly emergent diseases.
Novavax is involved in several international partnerships, including
collaborations with Cadila Pharmaceuticals of India, LG Life Sciences of Korea,
PATH and recently acquired Isconova AB, a leading vaccine adjuvant company
located in Sweden. Together, Novavax' network supports its global
commercialization strategy to create real and lasting change in the
biopharmaceutical and vaccinology fields. Additional information about Novavax
is available on the company's website, novavax.com. 

         Barclay Phillips
         SVP, Chief Financial Officer and Treasurer
         Novavax, Inc.
News Source: NASDAQ OMX

End of Corporate News


26.11.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de


Language:    English        
Company:     Novavax, Inc.  
             United States  
ISIN:        US6700021040   
End of News    DGAP News-Service  
241831 26.11.2013